Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial

MD Fischer, S Michalakis, B Wilhelm… - JAMA …, 2020 - jamanetwork.com
Importance Achromatopsia linked to variations in theCNGA3gene is associated with day
blindness, poor visual acuity, photophobia, and involuntary eye movements owing to lack of …
被引用次数：138 相关文章

Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial.

MD Fischer, S Michalakis, B Wilhelm, D Zobor… - JAMA …, 2020 - europepmc.org
Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in
Achromatopsia: A Nonrandomized Controlled Trial. - Abstract - Europe PMC Sign in | Create an …

Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial

MD Fischer, S Michalakis, B Wilhelm… - JAMA …, 2020 - pubmed.ncbi.nlm.nih.gov
Importance Achromatopsia linked to variations in the CNGA3 gene is associated with day
blindness, poor visual acuity, photophobia, and involuntary eye movements owing to lack of …
[HTML] nih.gov

[HTML][HTML] Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial

MD Fischer, S Michalakis, B Wilhelm, D Zobor… - JAMA …, 2020 - ncbi.nlm.nih.gov
Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in
Achromatopsia - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

[引用][C] Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia A Nonrandomized Controlled Trial

MD Fischer, S Michalakis, B Wilhelm… - Jama …, 2020 - tobias-lib.ub.uni-tuebingen.de
Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in
Achromatopsia A Nonrandomized Controlled Trial Safety and Vision Outcomes of …

Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia A Nonrandomized Controlled Trial

MD Fischer, S Michalakis, B Wilhelm… - Jama …, 2020 - epub.ub.uni-muenchen.de
IMPORTANCE Achromatopsia linked to variations in the CNGA3 gene is associated with
day blindness, poor visual acuity, photophobia, and involuntary eye movements owing to …

[引用][C] Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia A Nonrandomized Controlled Trial

MD Fischer, S Michalakis, B Wilhelm… - Jama …, 2020 - ub01.uni-tuebingen.de
Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in
Achromatopsia A Nonrandomized Controlled Trial Safety and Vision Outcomes of …
[PDF] researchgate.net

[PDF][PDF] Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia A Nonrandomized Controlled Trial

MD Fischer, S Michalakis, B Wilhelm, D Zobor… - researchgate.net
OBJECTIVE To assess safety and vision outcomes of supplemental gene therapy with
adeno-associated virus (AAV) encoding CNGA3 (AAV8. CNGA3) in patients with CNGA3 …

Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial.

MD Fischer, S Michalakis, B Wilhelm, D Zobor… - JAMA …, 2020 - europepmc.org
Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in
Achromatopsia: A Nonrandomized Controlled Trial. - Abstract - Europe PMC Sign in | Create an …